0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. "We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan," says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. (jason.chau@wsj.com)

(END) Dow Jones Newswires

February 10, 2026 00:18 ET (05:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.